Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

- Weber, Jeffrey S., Schadendorf, Dirk, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Del Vecchio, Michele, Brown, Michael P., Rutkowski, P, Haydon, A, Grob, J-J, Schachter, J, Queirolo, P, de la Cruz-Merino, L, van der Westhuizen, Andre, Menzies, AM, Re, S, Larkin, James, Bas, T, de Pril, V, Braverman, J, Tenney, DJ, Tang, H, Long, GV, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

- Hauschild, Axel, Agarwala, Sanjiv S, Peschel, Christian, Schadendorf, Dirk, Garbe, Claus, O'Day, Steven, Daud, Adil, White, J. Michael, Xia, Chenghua, Patel, Kiran, Kirkwood, John M., Keilholz, Ulrich, Trefzer, Uwe, Hogg, David, Robert, Caroline, Hersey, Peter, Eggermont, Alexander, Grabbe, Stephan, Gonzalez, Rene, Gille, Jens